PS166 Efficacy and Safety of Alirocumab According to Smoking Status

Studies have suggested that smokers have higher circulating levels of PCSK9 than non-smokers. We analyzed whether differential effects were seen with alirocumab treatment in smokers and non-smokers.

Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: A.C. Sposito, F.A. Fonseca, M. Averna, L.V. Lee, M.J. Louie, G. Asset, M. Farnier Tags: Poster Abstract Source Type: research